A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer

Carles Galceran, Joan; Chowdhury, Simon; McGregor, Bradley; Merseburger, Axel; Agarwal, Neeraj; Azad, Arun

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Carles Galceran, Joan
dc.contributor.author	Chowdhury, Simon
dc.contributor.author	McGregor, Bradley
dc.contributor.author	Merseburger, Axel
dc.contributor.author	Agarwal, Neeraj
dc.contributor.author	Azad, Arun
dc.date.accessioned	2022-08-11T06:09:05Z
dc.date.available	2022-08-11T06:09:05Z
dc.date.issued	2022-03
dc.identifier.citation	Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, et al. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Futur Oncol. 2022 Mar;18(10):1185-98.
dc.identifier.issn	1479-6694
dc.identifier.uri	https://hdl.handle.net/11351/7985
dc.description	Atezolizumab; Cabozantinib; Inhibidor del punt de control immunitari
dc.description.sponsorship	This study is funded by Exelixis but includes support (including the provision of atezolizumab) from Roche.
dc.language.iso	eng
dc.publisher	Future Medicine
dc.relation.ispartofseries	Future Oncology;18(10)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Pròstata - Càncer - Hormonoteràpia
dc.subject	Metàstasi
dc.subject.mesh	Prostatic Neoplasms, Castration-Resistant
dc.subject.mesh	/drug therapy
dc.subject.mesh	Antineoplastic Agents, Hormonal
dc.title	A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.2217/fon-2021-1096
dc.subject.decs	neoplasias prostáticas resistentes a la castración
dc.subject.decs	/farmacoterapia
dc.subject.decs	antineoplásicos hormonales
dc.relation.publishversion	https://doi.org/10.2217/fon-2021-1096
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Agarwal N] Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, USA. [Azad A] Peter MacCallum Cancer Centre & Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Chowdhury S] Guy’s, King’s & St. Thomas’ Hospitals, & Sarah Cannon Research Institute, London, UK. [McGregor B] Lank Center of Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. [Merseburger AS] Department of Urology, University Hospital Schleswig-Holstein, Lubeck, Germany
dc.identifier.pmid	35034502
dc.identifier.wos	000743733200001
dc.rights.accessrights	info:eu-repo/semantics/openAccess